Gene therapy of HSV-TK transferred by the EBV based expression vector on experimental hepatocellular carcinoma

Abstract

To study the therapeutic effects of herpes simplex virus thymidine kinase (HSV-TK) gene transferred by the EBV-based expression vector (pDR2) on experimental hepatocellular carcinoma, pDR2-TK gene was delivered into human hepatocellular carcinoma cell line SMMC-7721 by using liposome-mediated transfection technique, and then gene expression was detected by RT-PCR, and the killing effects were examined through MTT method. In the nude mice hepatoma model, the antitumor effects of pDR2-TK/GCV system was evaluated in terms of tumor growth. MTT results showed that the pDR2-TK/GCV had cytotoxic effect and about 70% SMMC-7721 cells were killed when GCV was at 1000 μmol/L.In vivo experiment showed that the tumor size in nude mice with transferred pDR2-TK gene was significantly smaller than that in control group (P< 0. 01). On the 10th day the tumor in 3 mice (60 %) disappeared completely after GCV treatment. It is concluded that the pDR2-TK/GCV system has marked killing effects on the experimental hepatocellular carcinoma.

Keywords

hepatocellular carcinoma / gene therapy / EB virus / expression vector / HSV-TK gene

References

[1] QianC, BilbaoR, BrunaO, et al.. Induction of sensitive to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology, 1995, 22(1): 118-118

[2] MosmannT. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytoxicity assays. J Immunol Methods, 1983, 65(1): 55-55

[3] KuriyamaS, NakataniT, MasuiK, et al.. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology, 1995, 22(6): 1838-1838

[4] TouraineR L, VahanianN, RamseyW J, et al.. Enhancemant of the herpes simplex virus thymidine kinase/ ganciclovir bystander effect and its antitumor efficacyin vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther, 1998, 9(16): 2385-2385

[5] FreemanS M, RameshR, MarogiA J. Immune system in suicide gene therapy. Lancet, 1997, 349(1): 2-2

[6] hsv-tk EB 1999, 16(3):153

[7] 1999, 16(1):40